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Abstract 
Hantaan virus (HTNV) causes severe human disease. The HTNV genome consists of three ssRNA 
segments of negative polarity that are complexed with viral nucleocapsid (N) protein. How the human 
innate immune system detects HTNV is unclear. RNA helicase retinoic acid-inducible gene I (RIG-I) 
does not sense genomic HTNV RNA. So far it has not been analysed whether pathogen-associated 
molecular patterns generated during the HTNV replication trigger RIG-I-mediated innate responses. 
Indeed, we found that knock‐down of RIG-I in A549 cells, an alveolar epithelial cell line, increases 
HTNV replication and prevents induction of 2′,5′-oligoadenylate synthetase, an interferon-stimulated 
gene. Moreover, overexpression of wild-type or constitutive active RIG-I in Huh7.5 cells lacking a 
functional RIG-I diminished HTNV virion production. Intriguingly, reporter assays revealed that in vitro-
transcribed HTNV N RNA and expression of the HTNV N ORF triggers RIG-I signalling. This effect 
was completely blocked by the RNA-binding domain of vaccinia virus E3 protein, suggesting that 
dsRNA-like secondary structures of HTNV N RNA stimulate RIG-I. Finally, transfection of HTNV N 
RNA into A549 cells resulted in a 2 log-reduction of viral titres upon challenge with virus. Our study is 
the first demonstration that RIG-I mediates antiviral innate responses induced by HTNV N RNA during 
HTNV replication and interferes with HTNV growth.  
 
Introduction 
Human infections with hantaviruses are on the rise due to enhanced human contact with rodents, their 
main reservoir (Ludwig et al., 2003; Schmaljohn & Hjelle, 1997; Ulrich et al., 2002). Humans are 
infected after inhalation of aerosols from excreta shed by chronically infected rodents that do not show 
obvious symptoms. The outcome of human infection is variable and depends on the infecting 
hantavirus species. Pathogenic hantavirus species elicit highly lethal diseases, hantavirus 
cardiopulmonary syndrome (HCPS) or haemorrhagic fever with renal syndrome (HFRS) (Krüger et al., 
2001; Muranyi et al., 2005). Hantaan virus (HTNV), the prototype member of the genus Hantavirus in 
the family Bunyaviridae, causes HFRS with a case fatality rate up to 15  %.  
Hantaviruses are enveloped and contain a tripartite ssRNA genome of negative polarity (Schmaljohn & 
Nichol, 2007). It consists of a small, medium and large segment that encode the nucleocapsid (N) 
protein, envelope glycoproteins (Gn and Gc) and RNA-dependent RNA polymerase (RdRp). The 5′ 
and 3′ termini of the hantaviral genome form a panhandle structure. HTNV replication starts with virion 
attachment to integrin β3 (CD61), a receptor for pathogenic hantaviruses (Gavrilovskaya et al., 1998, 
1999). Recently, decay-accelerating factor (CD55) and receptor for globular heads of C1q (gC1qR) 
have been defined as additional HTNV receptors (Choi et al., 2008; Krautkrämer & Zeier, 2008). After 
entry by endocytosis and acidification of endosomes fusion between endosomal membrane and viral 
envelope takes place. After release of the viral nucleocapsid into the cytoplasm the RdRp initiates 
transcription from genomic RNA. This results in production of positive-sense RNA, i.e. viral mRNA and 
  
antigenomic RNA (cRNA). The latter serves as a template for the generation of negative-sense 
genomic RNA (Jonsson & Schmaljohn, 2001). Hantaviral mRNA is transcribed in such a way that 3′-
truncated molecules are generated preventing the formation of a panhandle structure. Like other 
important human pathogens belonging to the family Bunyaviridae, hantaviruses start synthesis of viral 
mRNA through the process of cap-snatching (Garcin et al., 1995; Jin & Elliott, 1993; Mir & 
Panganiban, 2010).  
The immune system is assumed to play a crucial role in the development of hantavirus-associated 
disease (Schönrich et al., 2008). It detects virus through pattern recognition receptors (PRRs). Toll-like 
receptors (TLRs) and retinoic acid-inducible gene I (RIG-I)-like RNA helicases (RLHs), including RIG-I, 
represent two major classes of PRRs (Takeuchi & Akira, 2010). Whereas TLRs detect viral nucleic 
acid either at the cell surface or inside endosomes the RLHs survey the cytoplasm for virus-derived 
RNA (Eisenächer et al., 2008). The RLHs are found in all nucleated cells (Gilliet et al., 2008) and are 
involved in detection of many RNA viruses (Loo et al., 2008). Negative-sense genomic RNA purified 
from hantavirus virions released into the supernatant do not activate RIG-I (Habjan et al., 2008; Wang 
et al., 2011). On the other hand, pathogenic hantaviruses have been shown to interfere with RIG-I 
signalling pointing towards the importance of RIG-I for the hantaviral life cycle (Alff et al., 2006).  
In this study, we show that RIG-I inhibits HTNV replication and mediates an HTNV-induced antiviral 
innate response. Furthermore, we identify expression of the HTNV N ORF as a possible stimulus of 
RIG-I signalling.  
 
Results 
Generation of a stable RIG-I knock down in human type II alveolar cells 
The lung is the entry site for hantaviruses in humans. The alveolar epithelial cell line A549 supports 
hantavirus replication (Lee & Cho, 1981; Nam et al., 2003; Stoltz et al., 2007). Thus, we analysed 
these cells to test whether HTNV replication is regulated by RIG-I. Stable RIG-I knock-down (RIG-I 
KD) A549 cells were established by transfecting A549 cells with a retroviral vector expressing RIG-I-
specific small hairpin RNA (shRNA). RIG-I was not detectable in RIG-I KD A549 cells after treatment 
with type I interferon (IFN) (Fig. 1a). In contrast, A549 cells transfected with a vector expressing non-
target (nt) shRNA and parental A549 cells abundantly expressed RIG-I. Vesicular stomatitis virus 
(VSV), a known RIG-I stimulator (Kato et al., 2006; Yoneyama et al., 2005), replicated more efficiently 
in RIG-I KD than in nt shRNA or parental A549 cells (Fig. 1b). In conclusion, we have established a 
suitable experimental system to analyse the influence of RIG-I on hantavirus replication.  
Generation of stable RIG-I KD A549 cells. (a) A549 cells expressing RIG-I-specific shRNA (lane 1, 
RIG-I KD), A549 cells expressing nt shRNA (lane 2) and parental A549 cells (lane 3) were treated with 
type I IFN (500 U ml
−1
) before RIG-I expression was analysed by Western blot. (b) RIG-I KD, nt 
shRNA and parental A549 cells were infected with VSV (m.o.i. of 1). Supernatants were collected at 
different time points after infection as indicated. Virus titres were determined and are given as TCID50 
ml 
−1
 on a log scale. The experiment was carried out twice with different stable RIG-I KD A549 cell 
clones giving similar results.  
 
Increased virus replication in RIG-I KD A549 cells after HTNV infection 
The RIG-I KD A549 cell lines did not differ from parental A549 cells with regard to surface expression 
of known cellular HTNV receptors. Fig. 2(a) shows that CD61 was strongly expressed on Vero E6 cells 
but hardly detectable on parental and RIG-I KD A549 cells. In contrast, CD55 was found on parental 
and RIG-I KD A549 cells, whereas Vero E6 cells only weakly expressed this HTNV receptor. Finally, 
gC1qR expression was hardly detectable on both cell types. Next, we examined whether knock-down 
of RIG-I influenced the growth pattern of HTNV. Fig. 2(b) demonstrates that HTNV replicated much 
more efficiently in RIG-I KD cells than in parental A549 cells over a time period of 7 days. Together, 
these loss-of-function experiments demonstrate that RIG-I negatively regulates HTNV replication in 
human type II alveolar cells.  
  
 
Impaired HTNV replication in Huh7.5 cells expressing functional RIG-I 
The physiological importance of RIG-I for restricting HTNV replication was confirmed in a gain-of-
function experiment. For this purpose, we used Huh7.5 cells as they carry a mutated endogenous 
RIG-I allele which exerts a dominant-negative effect (Sumpter, et al., 2005). The latter is partially 
compensated in transduced Huh7.5 cells that overexpress functional RIG-I, wild-type or constitutive 
active RIG-I (Binder et al., 2007). The wild-type RIG-I molecule is maintained in an autoinhibited state 
and has to be stimulated by a ligand to undergo a conformational shift allowing innate signalling. In 
contrast, constitutive active RIG-I lacks the repressor domain, resulting in constitutive innate signalling 
(Saito et al., 2007). Parental and transduced Huh7.5 cells did not significantly differ with regard to 
HTNV receptor surface expression (Fig. 3a). CD55 was weakly expressed and expression of CD61 
and gCq1R was hardly detectable. HTNV replicated more efficiently in parental Huh7.5 cells as 
compared with transduced Huh7.5 cells expressing a functional RIG-I (Fig. 3b). The inhibitory effect of 
both wild-type or constitutive active RIG-I on HTNV replication was relatively weak probably because 
they had to overcome the dominant-negative effect of mutated endogenous RIG-I. Most importantly, 
however, the extent of HTNV growth inhibition was similar in Huh7.5 cells expressing wild-type or 
constitutive active RIG-I. Thus, HTNV efficiently stimulates wild-type RIG-I, resulting in downregulation 
of HTNV replication.  
 
Lack of antiviral innate responses in stable RIG-I knock-down cells after HTNV infection 
Next, we connected HTNV replication with the antiviral innate response. For this purpose, we tested 
expression of 2′,5′-oligoadenylate synthetase (OAS), an important IFN-stimulated gene that is induced 
by HTNV in A549 cells (Nam et al., 2003). As shown in Fig. 4, hardly any OAS transcripts were 
detected in parental and RIG-I KD A549 cells that were uninfected but otherwise treated in the same 
way as HTNV-infected A549 cells (mock). Intriguingly, after HTNV infection parental but not RIG-I KD 
A549 cells upregulated OAS expression, demonstrating that HTNV-induced antiviral innate responses 
were severely hampered in the absence of RIG-I. However, both parental and RIG-I KD A549 cells 
strongly expressed OAS after treatment with type I IFN, showing that RIG-I KD A549 cells were in 
principle responsive to this signature cytokine of viral infections. In conclusion, increased HTNV 
replication in alveolar epithelial cells that lack RIG-I was linked to the inability to induce an antiviral 
innate response.  
 
RIG-I stimulation by expression of the HTNV N ORF 
We performed dual luciferase reporter assays in human HEK 293T cells to identify HTNV-derived RNA 
that triggers the RIG-I pathway. In line with a previous report (Habjan et al., 2008), IFN-β promoter 
activity was not significantly induced by genomic HTNV RNA (data not shown). As genomic HTNV 
RNA is of negative polarity, it was still possible that positive-sense HTNV RNA triggers RIG-I 
signalling. To test this hypothesis, plasmids (pcDNA3) expressing either the N or G ORF were co-
transfected with an IFN-β promoter-based RIG-I reporter system into human HEK 293T cells. It is 
important to note that pcDNA3-derived DNA alone does not stimulate IFN-β promoter activity in 
transfected HEK 293T cells (Ablasser et al., 2009). Thus, transfection of empty pcDNA3 (vector) 
marks the background level caused by overexpression of the RIG-I reporter system. Intriguingly, RIG-I 
signalling was significantly stimulated by plasmids expressing the HTNV N ORF as compared with 
vector (Fig. 5a, left graph). In striking contrast, plasmids expressing the HTNV G ORF did not activate 
RIG-I (Fig. 5a, right graph). The NS1 ORF of influenza B virus, a RIG-I blocker (Wolff et al., 2008), 
even diminished RIG-I activity below background level. Moreover, expression plasmids with inverted N 
ORF did not stimulate RIG-I after co-transfection with the RIG-I reporter system into HEK 293T cells, 
suggesting that negative-sense HTNV N RNA is not stimulatory (data not shown).  
Next we verified that HTNV N RNA triggers IFN-β promoter activity via RIG-I. For this purpose 
uncapped HTNV N RNA was generated by in vitro transcription. After transfection of uncapped HTNV 
N RNA into HEK 293T cells RIG-I stimulation was significantly increased compared with the vector 
control (Fig. 5b, left graph). In striking contrast, in vitro-transcribed G RNA did not modulate RIG-I 
signalling as compared to the vector control (Fig. 5b, right graph).  
  
Now, we compared HTNV N ORF expression plasmids to known stimulators of RIG-I signalling, 
poly(dA : dT) (Ablasser et al., 2009; Chiu et al., 2009) and VSV RNA (Kato et al., 2006; Yoneyama et 
al., 2005). Fig. 6(a) demonstrates that after transfection into HEK 293T cells 1 µg of HTNV N ORF 
expression plasmid was as efficient as 0.5 µg poly(dA  : dT) in activating RIG-I signalling compared with 
the vector. In contrast, VSV RNA showed a higher RIG-I stimulatory capacity. Similar results were 
obtained using an NF-κB promoter-based reporter system (Fig. 6b). Altogether, these results show 
that HTNV N ORF expression significantly triggers RIG-I signalling.  
 
HTNV N ORF expression stimulates RIG-I through dsRNA structures 
It has been shown recently that dsRNA-like secondary structures play a pivotal role in RIG-I 
stimulation (Baum et al., 2010; Fujita, 2009; Schlee et al., 2009; Schmidt et al., 2009). To test this 
hypothesis, we used a pcDNA4 vector expressing the C terminus (Δ83N, aa 84–190) of the vaccinia 
virus E3 protein (Valentine & Smith, 2010). Δ83N represents a well described dsRNA-binding domain 
that sequesters dsRNA (Chang & Jacobs, 1993; Watson et al., 1991) and has been demonstrated to 
block the RIG-I stimulatory effect of poly(dA : dT) (Valentine & Smith, 2010). Intriguingly, Δ83N 
completely blocked the RIG-I stimulatory effect of HTNV N ORF expression (Fig. 7). In contrast, Δ83N 
did not abrogate the background level caused by the RIG-I reporter system (vector control). These 
findings indicate that dsRNA-like secondary structures of HTNV N RNA stimulate RIG-I.  
 
Antiviral response after transfection of HTNV N RNA into A549 cells 
To test the idea that HTNV N RNA induces an antiviral response through endogenous RIG-I A549 
cells were transfected with in vitro-transcribed N RNA. Subsequently, cells were challenged with VSV 
and the viral titres were determined (Fig. 8). Indeed, transfection of in vitro-transcribed N RNA resulted 
in a 2 log-reduction upon VSV challenge compared to the control (mock transfection). Pre-treatment 
with poly(dA : dT) caused a similar reduction. As expected, pre-treatment with type I IFN reduced viral 
titres even more strongly. Importantly, treating in vitro-transcribed HTNV RNA with calf intestinal 
alkaline phosphatase (CIAP), which catalyses the hydrolysis of 5′-triphosphate groups from RNA, only 
slightly diminished the induction of an antiviral innate response. This suggests that the presence of 5′-
triphosphate is less important for the RIG-I stimulation by HTNV N RNA. Taken together, these results 
show that HTNV N RNA induces an antiviral innate response that interferes with viral replication.  
 
Discussion 
After infection with HTNV, we found strongly enhanced virus replication in RIG-I KD A549 cells as 
compared with parental cells. This suggests that RIG-I acts as a cytoplasmic sensor of replicating 
HTNV as parental and RIG-I KD A549 cells did not differ with regard to hantavirus receptor 
expression. The role of RIG-I as a negative regulator of HTNV replication was confirmed by a gain-of-
function experiment using Huh7.5 cells that lack functional RIG-I (Sumpter, et al., 2005). In stably 
transduced Huh7.5 cells that overexpress wild-type or constitutive active RIG-I the sensitivity to RIG-I 
stimulatory virus is partially restored (Binder et al., 2007). Similar to A549 cells Huh7.5 cells expressed 
CD55 as a HTNV receptor but not CD61 or gC1qR. Intriguingly, in HTNV-infected Huh7.5 cells 
expressing wild-type RIG-I and Huh7.5 cells expressing constitutive active RIG-I the extent of HTNV 
growth inhibition was comparable. In contrast to constitutive active RIG-I the wild-type RIG-I molecule 
has to be activated by a ligand to relay downstream signalling (Saito et al., 2007), suggesting that 
HTNV stimulates wild-type RIG-I efficiently. Taken together, by using two different experimental 
approaches, a loss-of-function and a gain-of-function RIG-I system, we could demonstrate that RIG-I 
negatively regulates HTNV replication.  
Confirming a previous report (Nam et al., 2003), we found that HTNV-infected A549 cells upregulate 
OAS, an essential player during antiviral innate responses (Roberts et al., 1976). In striking contrast, in 
RIG-I KD A549 cells no induction of OAS was observed despite strongly increased HTNV replication. 
Exogenous type I IFN induced OAS expression in parental and RIG-I KD A549 cells to the same 
extent, excluding an intrinsic defect in antiviral innate responses of RIG-I KD A549 cells. In conclusion, 
these results clearly show that the antiviral innate response against HTNV is severely impaired in the 
absence of RIG-I allowing HTNV to replicate more efficiently.  
  
OAS represents a PRR on its own that is located in the cytoplasm as an inactive monomer 
(Chakrabarti et al., 2011). It is activated by some form of dsRNA (Minks et al., 1979) similar to TLR3. 
In addition, ssRNA has been shown to stimulate OAS (Hartmann et al., 1998). Upon stimulation OAS 
generates 2′,5′-oligoadenylates from ATP (Kerr & Brown, 1978). Predominantly 2′,5′-oligoadenylate 
trimers and longer oligomers subsequently activate RNase L (Hovanessian et al., 1979), a cellular 
endoribonuclease that cleaves cellular and viral RNA within single-stranded loop regions. Intriguingly, 
some of the resulting cleaving products stimulate RIG-I (Malathi et al., 2007, 2010). Thus, RNA 
molecules derived from replicating HTNV may stimulate RIG-I indirectly through the OAS/RNase L 
pathway.  
The nature of HTNV RNA that activates RIG-I is unclear. Genomic HTNV RNA did not significantly 
trigger RIG-I (data not shown) confirming observations by other investigators (Habjan et al., 2008). 
This may be due to the prime-and-realign mechanism during initiation of hantaviral genome replication 
(Garcin et al., 1995). It removes possible RIG-I stimulating 5′-triphosphates and creates 
complementary 5′- and 3′-ends forming a panhandle structure. Hantaviral N protein trimers specifically 
bind to the panhandle conformation to encapsidate the genomic RNA during replication (Mir et al., 
2006; Mir & Panganiban, 2004, 2005). In this way the likelihood of innate responses induced by 
genomic hantavirus RNA is further reduced because panhandle structures potentially activate RIG-I 
(Baum et al., 2010; Fujita, 2009; Schlee et al., 2009; Schmidt et al., 2009). In contrast to genomic 
hantavirus RNA panhandles formed by hantavirus cRNA interact at much lower affinity with N protein 
trimers (Mir & Panganiban, 2005). Thus, they are more accessible to RIG-I as compared with genomic 
hantavirus RNA. It remains to be investigated, however, whether hantaviral cRNA is RIG-I stimulatory.  
Intriguingly, N but not G ORF expression induced RIG-I signalling. The plasmid expressing NS1 
protein of influenza B virus, a RIG-I inhibitor (Wolff et al., 2008), even diminished RIG-I activity below 
background level. It is unlikely that the N protein itself triggers RIG-I signalling. The N-terminal 
caspase activation and recruitment domain (CARD) of RIG-I is masked by the RNA-binding C-terminal 
domain (Cui et al., 2008; Takahasi et al., 2008). Appropriate RNA structures, therefore, have to 
interact with this domain to induce conformational changes that expose CARD and allow downstream 
RIG-I signalling. Strongly supporting this view, the RNA-binding domain of vaccinia virus E3 protein 
(Chang & Jacobs, 1993; Watson et al., 1991) completely blocked the RIG-I stimulatory effect of HTNV 
N ORF expression. Moreover, it has been demonstrated that N protein inhibits rather than stimulates 
innate responses (Levine et al., 2010; Ontiveros et al., 2010; Taylor et al., 2009).  
In vitro-transcribed N but not G RNA containing 5′-triphosphate activated RIG-I. This finding is 
explained by recent publications showing that 5′-triphosphate is not sufficient to trigger RIG-I signalling 
(Baum et al., 2010; Fujita, 2009; Schlee et al., 2009; Schmidt et al., 2009). Thus, N but not G RNA 
may form dsRNA-like secondary structures that are crucial for RIG-I activation. These higher order 
structures may be bound and sequestered by the RNA-binding domain of vaccinia virus E3 protein 
explaining its inhibitory effect. As no dsRNA can be detected in HTNV-infected cells with dsRNA-
specific J2 antibody (Wang et al., 2011) dsRNA regions within HTNV N RNA may be smaller than 40 
bp, the detection limit of J2 (Bonin et al., 2000). In line with this view, crystallographic studies revealed 
that dsRNA of 14 bp and lacking 5′-triphosphate bind to RIG-I (Lu et al., 2011). Alternatively, one 
dsRNA molecule per cell is sufficient to stimulate generation of type I IFN (Marcus & Sekellick, 1977) 
and RIG-I may be more sensitive in detecting dsRNA than dsRNA-specific antibodies.  
Transfection of in vitro-transcribed HTNV N RNA into A549 cells resulted in a 2 log-reduction of viral 
titres upon VSV infection. This finding underlines the physiological importance of HTNV N RNA as a 
stimulus of antiviral innate responses. Intriguingly, a similar reduction was observed when the 5′-
triphosphate groups of in vitro-transcribed HTNV N RNA were removed by CIAP treatment. Thus, 
dsRNA-like secondary structures rather than 5′-triphosphate seem to determine the RIG-I stimulatory 
capacity of HTNV N RNA. This explains why N mRNA triggers RIG-I signalling although the 5′-
triphosphate is masked by a 7-methylguanosine cap. In accordance with this view, it has been recently 
shown that RIG-I detects synthetic short dsRNA without 5′-triphosphate (Kato et al., 2008; Takahasi et 
al., 2008).  
The extent of RIG-I stimulation by N ORF expression plasmids was comparable to that observed with 
poly(dA : dT). This synthetic dsDNA is transcribed by DNA-dependent polymerase III into RNA 
molecules containing 5′-triphosphate ends that are sensed by RIG-I (Ablasser et al., 2009; Chiu et al., 
2009). However, a role for DNA-dependent RNA polymerase III in our dual luciferase assays can be 
excluded for several reasons. The HTNV ORF lacks a long stretch of homopolymeric AT that is 
  
required for recognition by RNA polymerase III. Moreover, RNA polymerase III transcribes AT-rich 
dsDNA in a promoter-independent fashion (Ablasser et al., 2009). Accordingly, an expression plasmid 
with inverted N ORF should also stimulate RIG-I. However, this was not observed (data not shown).  
In general viruses are detected by several PRRs at multiple checkpoints during the viral life cycle. For 
hantaviruses the following scenario could be envisaged. After receptor binding before viral entry there 
could be a first checkpoint for hantaviruses (Jiang et al., 2008; Prescott et al., 2005, 2007). 
Subsequently, after phagocytosis of HTNV-infected, apoptotic cells HTNV-derived dsRNA could 
trigger TLR3 in endosomal compartments (Handke et al., 2009). We identified RIG-I, a cytoplasmic 
PRR, as a further checkpoint. It is likely that all PRRs stimulated by hantaviral components act 
synergistically to induce antiviral innate responses. Future studies have to elucidate the precise nature 
of hantaviral RNA structure(s) that trigger RIG-I activity. These efforts will finally lead to a better 
understanding of the molecular mechanisms that allow discrimination between ‘self’ and virus-derived 




HTNV (strain 76-118) was propagated in Vero E6 cells in a biosafety level 3 facility as described 
previously (Kraus et al., 2004). The VSV Indiana strain (laboratory-adapted Mudd-Summers isolate) 
was propagated in Vero E6 cells. At 24 h post-infection (p.i.), supernatants were centrifuged at 2000 g 
to clear cellular debris, aliquoted and frozen at −80 °C.  
 
Virus titration. 
Hantavirus titres were determined as described previously (Heider et al., 2001). Briefly, Vero E6 cells 
were infected by serial dilutions of supernatants for 1 h to allow absorbance of virus particles. 
Thereafter, cells were overlaid with medium containing 0.5  % agarose. After 7 days of incubation at 37 
°C the overlay was removed, cells were washed with PBS and fixed with methanol for 10 min. After 
incubation with a hantavirus N protein-specific polyclonal rabbit serum the SuperSignal West Dura 
Extended Duration Substrate kit (Pierce/Perbio) was used according to the manufacturer’s instructions 




VSV was titrated on Vero E6 cells in a 10-fold serial dilution in quadruplets. At 24 h p.i., cells were 
fixed with formaldehyde and stained with crystal violet. TCID50 values were calculated by the 
Spearman–Kaerber method. For titration of supernatants from VSV-infected A549 cells plaque assays 
were performed. Cells were fixed with 1 % paraformaldehyde and stained with crystal violet. Titres 





HEK 293T cells were maintained in Dulbecco’s modified Eagle’s medium supplemented with 10 % 
FCS, 2 mM l-glutamine, penicillin and streptomycin (Gibco-Invitrogen). Vero E6 cells were grown in 
minimal essential medium supplemented with the same additives.  
For generation of A549 RIG-I knock-down cell lines, pSM2c-derived plasmids containing RIG-I specific 
and nt shRNA expression cassettes (Expression Arrest human retroviral shRNA
mir
 individual 
constructs; oligo ID V2HS 199776 and RHS1707, respectively) were obtained from Open Biosystems 
through BioCat and checked by sequencing using a U6 promoter-specific primer. A549 cells 
purchased from ATCC were reverse transfected (8th passage) in 100 mm cell culture dishes using 30 
µl Lipofectamine 2000 (Gibco-Invitrogen) and 15 µg of the pSM2c-derived plasmids according to the 
manufacturer’s protocol. After 12–18 days of puromycin selection (2 µg ml
−1
) single clones were 
picked and transferred to 48-well plates, while the nt shRNA expressing clones were pooled. All cells 




Huh7.5 cells that are derived from a human hepatoma cell line (Blight et al., 2002) express an 
endogenous RIG-I with a mutation (T55I) in the first caspase-recruiting domain. It binds viral RNA but 
is unable to transduce signals thereby acting as a dominant-negative inhibitor (Sumpter, et al., 2005). 
Transduced Huh7.5 clones overexpressing WT RIG-I or CA RIG-I have been generated previously 
(Binder et al., 2007). Culture conditions for Huh7.5 parental cells and clones were according to 
Quinkert et al. (2005). All cell lines used were free of mycoplasma as tested by PCR-based VenorGeM 
mycoplasma detection kit (Minerva Biolabs).  
 
Western blot. 
Western blot analysis was performed as described previously (Lütteke et al., 2010). RIG-I- and β-
actin-specific antibodies were purchased from Alexis Biochemicals. For detection of primary antibodies 
an anti-rabbit or anti-mouse peroxidase-conjugated antibody (Amersham, GE Healthcare) was used.  
 
RNA preparation. 
Total viral RNA from supernatants of Vero E6 cells infected for 8 days (m.o.i. of 1) with HTNV or 
uninfected Vero E6 cells (mock) were isolated with TRIzol reagent (Gibco-Invitrogen) according to the 
manufacturer’s instructions. Subsequently, RNA concentrations were determined by photometric 
analyses. VSV RNA was prepared from supernatants of Vero E6 cells infected for 24 h with VSV. 
Virus was ultracentrifuged at 25000 r.p.m. (SW 32Ti; Beckman Coulter) using a sucrose density 




Expression plasmids derived from pcDNA3 and encoding HTNV N protein or G glycoprotein precursor 
molecule were used. The ORFs were cloned into pcDNA3 vector between sites EcoRI and XbaI. The 
nucleotide sequence of the entire ORF of each expression plasmid was confirmed by sequencing 
using the BigDye Terminator 3.1 kit (Applied Biosystems) and ABI Prism 3100 genetic analyser 
(Applied Biosystems). Data were evaluated with Sequencing Analyses 3.7 software.  
 
In vitro transcription.  
The pcDNA3-derived expression plasmids were digested with ApaI (Fermentas). Subsequently, in 
vitro-transcription was performed using T7 polymerase (Fermentas) according to the manufacturer’s 
protocol. After treatment with DNase, the RNA was purified by phenol/chloroform extraction or with 
RNAeasy Mini kit (Qiagen), washed with ice-cold 75 % ethanol and immediately used for experiments. 
An aliquot of each in vitro-transcribed RNA sample was analysed by RNA gel electrophoresis to verify 
its integrity (data not shown). To test the influence of 5′-triphosphates, aliquots of in vitro-transcribed 
RNAs were treated with CIAP (Fermentas) for 3 h at 37 °C. Thereafter, the samples were purified by 
phenol/chloroform extraction as described above.  
 
LightCycler quantitative RT-PCR. 
The quantitative RT-PCR analysis was performed as described previously (Lütteke et al., 2010).  
 
Dual luciferase assay. 
Duplicate wells of subconfluent HEK 293T cells were transfected with 50 ng IFN-β promoter luciferase 
reporter plasmid p125-Luc (Yoneyama et al., 1996) or NF-κB-driven Firefly luciferase plasmid 
(Stratagene) and 5 ng of constitutively active renilla luciferase expression vector pRL-TK-Luc 
(Stratagene) using Lipofectamine 2000 (Gibco-Invitrogen). To assess the RIG-I stimulatory activities, 
  
cells were co-transfected with 1 µg expression plasmids (HTNV N ORF or HTNV G ORF) or 500 ng of 
viral RNA generated by in vitro transcription, respectively, together with 100 ng of RIG-I expression 
plasmid (pEF-Bos-RIG-I Flag; Yoneyama et al., 2004). For each sample, transfections were done in 
parallel without RIG-I expression plasmid to assess background activity due to possible stimulation of 
endogenous pattern recognition receptors. Cells were lysed at 24 h post-transfection in 1× passive 
lysis buffer (Promega) by incubation for 15 min at 25 °C with gentle agitation. Subsequently, firefly 
luciferase reporter activity was assayed 24 h after transfection and normalized to renilla luciferase 
activity. All luciferase assays were performed at least three times with similar results using the Dual-
Luciferase Reporter Assay System (Promega) and a LB96V luminometer (Berthold). Empty pcDNA3 
vector was used as negative control; a vector expressing the non-structural protein of influenza B virus 
(B/NS1) was used as positive control for inhibition (Dauber et al., 2004). For every sample appropriate 
expression of RIG-I was verified by Western blot analysis (data not shown). Poly(dA  : dT) (Enzo Life 
Sciences) was used as a positive control for RIG-I stimulation. For inhibition of RIG-I stimulation by 
HTNV N ORF expression Δ83N inserted into pcDNA4 (Valentine & Smith, 2010) was used.  
 
Flow cytometry. 
Flow cytometry was performed as described previously (Lütteke et al., 2010). The following primary 
antibodies were used: anti-β3, clone C17 (Immunotools); anti-CD55/DAF, clone 143-30 (Southern 
Biotechnology); and anti-gC1qR, clone 74.5.2 (Chemicon). As secondary antibody PE-coupled goat 
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Figure 1. Generation of stable RIG-I KD A549 cells. (a) A549 cells expressing RIG-I-specific shRNA 
(lane 1, RIG-I KD), A549 cells expressing nt shRNA (lane 2) and parental A549 cells (lane 3) were 
treated with type I IFN (500 U ml
−1
) before RIG-I expression was analysed by Western blot. (b) RIG-I 
KD, nt shRNA and parental A549 cells were infected with VSV (m.o.i. of 1). Supernatants were 
collected at different time points after infection as indicated. Virus titres were determined and are given 
as TCID50 ml 
−1
 on a log scale. The experiment was carried out twice with different stable RIG-I KD 




Figure 2. Receptor expression and growth kinetics in RIG-I KD A549 cells. (a) Vero E6, parental and 
RIG-I KD A549 cells were stained for CD61, CD55 or gC1qR (grey filled histograms). Cells incubated 
with secondary antibody alone served as a control (unfilled histograms). The x-axis and y-axis indicate 
fluorescence intensity (log scale) and cell counts, respectively. Numbers in the upper right-hand corner 
represent mean fluorescence intensities. The data shown are representative for two independent 
experiments. (b) Parental and RIG-I KD A549 cells were infected with HTNV (m.o.i. of 1). 
Supernatants were collected at different time points and virus titres were determined by 
chemiluminescence focus assay (f.f.u. ml
−1
; log scale). The results represent one of three independent 



























Figure 3. Receptor expression and growth kinetics in transduced Huh7.5 cells. (a) Parental cells and 
transduced cells expressing wild-type (WT) or constitutive (CA) RIG-I were stained for CD61, CD55 or 
gC1qR (grey filled histograms). Cells incubated with secondary antibody alone served as a control 
(unfilled histograms). The x-axis and y-axis indicate fluorescence intensity (log scale) and cell counts, 
respectively. Numbers in the upper right-hand corner represent mean fluorescence intensities. The 
data shown are representative for two independent experiments. (b) After infection with HTNV (m.o.i. 
of 1) supernatants from parental, WT RIG-I and CA RIG-I Huh7.5 cells were collected at different time 
points and virus titres were determined by chemiluminescence focus assay (f.f.u. ml
−1











Figure 4. Antiviral innate response in RIG-I KD and parental A549 cells after HTNV infection. RIG-I 
KD and parental A549 cells as indicated were left uninfected (mock) or infected with HTNV (m.o.i. of 
1.5). RNA was isolated at 4 days p.i. and the relative abundance of transcripts encoding 2′,5′-OAS was 








Figure 5. Induction of RIG-I signalling by HTNV-associated RNA. (a) Plasmids (1 µg) encoding HTNV 
N (N ORF, left graph) or HTNV G (G ORF, right graph) were transfected into HEK 293T cells together 
with an IFN-β promoter-based RIG-I reporter system (50 ng IFN-β promoter-dependent firefly 
luciferase reporter plasmid p125-Luc, 5 ng constitutively active renilla luciferase expression vector 
pRL-TK-Luc and 100 ng RIG-I expression plasmid). As controls the same amount of empty pcDNA3 
(vector) or plasmid expressing NS1 of influenza B (Flu B/NS1) was transfected together with the RIG-I 
reporter system. (b) RNA (0.5 µg) derived from in vitro transcription of the HTNV N (left graph) or G 
(right graph) expression plasmid was transfected into HEK 293T cells together with the RIG-I reporter 
system. Results are shown as fold activation (mean±sd) of p125-Luc after normalization to renilla 
luciferase expression. They are derived from three independent experiments with transfections 




Figure 6. RIG-I stimulatory capacity of HTNV N ORF expression in dual luciferase assays. (a) 
Transfection of an IFN-β promoter-based RIG-I reporter system together with 1 µg empty pcDNA3 
(vector), 1 µg HTNV N expression plasmid (N ORF), 0.5 µg poly(dA  : dT) or 1 µg genomic VSV RNA 
into HEK 293T cells. (b) Transfection of an NF-κB promoter-based RIG-I reporter system together with 
1 µg empty pcDNA3 (vector), 1 µg HTNV N expression plasmid (N ORF), 0.5 µg poly(dA  : dT) or 1 µg 
genomic VSV RNA into HEK 293T cells. Results are shown as fold activation (mean±sd) of p125-Luc 
and pNF-κB-Luc, respectively, after normalization to renilla luciferase expression driven by a 
constitutive promoter. They are derived from three independent experiments with transfections 








Figure 7. dsRNA-binding domain of vaccinia virus E3 protein (Δ83N) inhibits RIG-I stimulation by 
HTNV N ORF expression. 293T cells were co-transfected with 1 µg empty pcDNA3 (vector), 1 µg 
HTNV N expression plasmid (N ORF) or 0.5 µg poly(dA  : dT) together with 1 µg Δ83N plasmid or empty 
pcDNA4 (vector) and IFN-β promoter-based RIG-I reporter system (50 ng p125-Luc, 5 ng pRL-TK, 
100 ng RIG-I expression plasmid). Results are shown as fold change (mean±sem) of p125-Luc after 
normalization to renilla luciferase expression. They are derived from two independent experiments 
with transfections performed in triplicate. Statistical analysis was performed by an F-test to determine 








Figure 8. HTNV N RNA protects A549 cells upon VSV challenge. In vitro-transcribed HTNV N RNA 
(0.5 μg) were left untreated or treated with CIAP to remove 5′-triphosphate and transfected into A549 
cells. As a positive control A549 cells were treated with poly(dA  : dT) (0.5 µg) or type I IFN (2000 U 
ml
−1
). After 24 h cells were infected with VSV (m.o.i. of 1). Supernatants from infected cells were 
collected 24 h p.i. and viral titres were measured by plaque assay. Results are shown as p.f.u. ml
−1
 
(mean±sd) derived from two independent experiments (*P<0.05, **P<0.005; Student’s t-test).  
 
 
 
 
